Monthly return of equity issuer on movements in securities for the month ended 30 september 2026
Filed with HKEX · Stock code 9688 · · 11 pages · English
Earlier from Zai Lab
- Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
- Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates